Premium
Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel–Lindau disease
Author(s) -
Sardi Iacopo,
Sanzo Massimiliano,
Giordano Flavio,
Buccoliero Anna Maria,
Mussa Federico,
Aricò Maurizio,
Genitori Lorenzo
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22065
Subject(s) - medicine , hemangioblastoma , thalidomide , von hippel–lindau disease , disease , antiangiogenic therapy , spinal cord , blood cancer , cancer , surgery , psychiatry , multiple myeloma
Abstract Von Hippel–Lindau (VHL) disease is a cancer‐prone syndrome characterized by abnormalities in vascular proliferation and the development of both the visceral and CNS tumors. Complications from hemangioblastoma are among the principal causes of death from this syndrome. Antiangiogenic therapy has been used with different modalities in patients suffering from such complications. Here, we describe an adolescent with VHL complicated by progressive, multifocal spinal hemangioblastomas. Treatment with single‐agent thalidomide over the course of 3 years was associated with an unexpected stabilization of the disease. The antiangiogenic effect of thalidomide may be associated with the control of progressive hemangioblastoma. Pediatr Blood Cancer 2009;53:464–467. © 2009 Wiley‐Liss, Inc.